Avita Medical, a regenerative medicine company, has signed an exclusive distribution deal for China with Sinopharm
The deal, signed in Beijing on Thursday with Sinopharm’s MedTech subsidiary, grants exclusive distribution of the Avita range of medical devices, which rapidly deliver a cellular suspension to trigger healing in burns, chronic wounds and aesthetic conditions.
Avita has been active in the China market for five years, with sales in the main cities of Beijing, Shanghai and Guangzhou.
Avita said its focus has primarily been in the fields of plastics and repigmentation, with a presence in several hospitals.
State-owned Sinopharm is involved in distribution, retail sales, research and development (R&D) and the manufacture of various healthcare-related products.
Avita Medical will provide clinical support to the Sinopharm MedTech sales team and extended agent network, to help with interactions with medical professionals.
The Company said the support strategy would also involve backing new research into Avita’s regenerative medicine approach, given the positive interactions with Chinese researchers to date.
Avita CEO Adam Kelliher, said: “Sinopharm MedTech have a proven track record of building up strong recurrent sales of medical devices and we greatly look forward to supporting their efforts in growing the China market.”
Qiu Shiru, general manager of Sinopharm Med-Tech’s Beijing office, said the company viewed ReCell to be a, “significant milestone product in the field of regenerative medicine, as it not only heals physical wounds, but also supports mental health.
“We regard it as a great honour to be the exclusive distributor of ReCell in China."
The Chinese distributor deal is the eighth territory to be signed by Avita in the past three months.